Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Abstract. Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. B...
Main Authors: | Le-Sang Shen, Xiao-Yan Jin, Xu-Meng Wang, Lai-Zhen Tou, Jian Huang, Qiang Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2020-05-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000000745 |
Similar Items
-
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
by: Abdel-Razeq H
Published: (2016-10-01) -
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer
by: Hikmat Abdel-Razeq
Published: (2019-03-01) -
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
by: Gradishar WJ
Published: (2016-07-01) -
Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
by: Adam M. Brufsky
Published: (2015-01-01) -
Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
by: Adam M. Brufsky
Published: (2015-12-01)